SAHM Issues Statement Supporting New HPV Vaccine

February 16, 2016

The Society for Adolescent Health and Medicine (SAHM) has issued a statementsupporting the use of a new, recently-approved HPV vaccine by the Centers for Disease Control and Prevention (CDC). The vaccine, 9vHPV, is used to protect against HPV-related disease and provides protection against more than double the number of HPV types than other vaccines, resulting in broader disease protection.

The nine-valent human papillomavirus vaccine (9vHPV) vaccine prevents an additional five types of HPV-attributable cancers. Previously approved vaccines prevent the two HPV types that account for about 66% of cervical cancers, and the nine-valent vaccine protects against the five types that account for an additional 15% of cervical cancers. In their report, the CDC determined that not only did the 9vHPV vaccine prevent more disease than the previously-used 4vHPV vaccine, but it was also more cost effective.

In February, 2015, the Advisory Committee on Immunization Practices (ACIP) voted to recommend 9vHPV for routine use among males and females age 11-12 years, with catch-up for females age 13-26 years, males age 13-21 years, and males age 22-26 years who are MSM (men who have sex with men), are immunocompromised, or choose to be vaccinated. Males and females may be immunized as young as 9 years of age. SAHM strongly recommends the use of 9vHPV among all adolescents and young adults for whom it is indicated. 

For further details, please see the report from the CDC:

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices 

Scroll to Top